People · Operator
Named in public records as an officer, director or promoter · active 2011–2022 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | — | Pharmaceuticals | Series D+ | $205.2M | $2.8B | 2013 |
| Verastem, Inc. | — | Pharmaceuticals | Series C | $163.2M | $3.5B | 2011 |
| Ribon Therapeutics, Inc. | — | Biotechnology | Series B | $119.1M | $343.2M | 2022 |
| Collegium Pharmaceutical, Inc | — | Pharmaceuticals | Series C | $97.5M | $701.8M | 2015 |
Paul Brannelly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Brannelly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Kauffman | 2 | 2 |
| David Hirsch | 1 | 16 |
| Jonathan Root | 1 | 16 |
| Patrick Heron | 1 | 11 |
| Cameron Wheeler | 1 | 9 |
| Christoph Westphal | 1 | 8 |
| Stephen Hoffman | 1 | 7 |
| John Freund | 1 | 7 |
| Timothy Barberich | 1 | 6 |
| Michael Heffernan | 1 | 5 |
| John K. Clarke | 1 | 5 |
| Gino Santini | 1 | 5 |
| Jeff Goater | 1 | 4 |
| Eric Rowinsky | 1 | 4 |
| Sharon Shacham | 1 | 4 |
| Robert Forrester | 1 | 4 |
| Ansbert K Gadicke | 1 | 4 |
| Eran Nadav | 1 | 4 |
| Emma Reeve | 1 | 4 |
| Michael Mason | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.